In a recent study posted to the bioRxiv preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).
In a new study, researchers assessed the stability of ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage in human biological fluids.
Researchers conducted phase 3 evaluations of the immunogenicity of the two immunization timeframes of the CoronaVac COVID-19 vaccine among Chilean adults.